Skip to main content
. 2019 Mar 1;90(7):796–804. doi: 10.1136/jnnp-2018-320113

Table 2.

Non-invasive neuromodulation clinical trials in acute migraine treatments

Device type* Studies (n) Enrolled
population (total n)
Both aura and no aura patients included (%) Blinded studies
(n)†
Sham-controlled studies (n) Percentage of studies evaluating IHS-recommended endpoints
Primary (%)‡ Secondary (%)‡
Electrical nerve stimulation
 Non-invasive vagus nerve stimulation (nVNS) 4 396 100 2 2 100 100
 External trigeminal nerve stimulation (e-TNS) 3 196 100 1 1 33 100
 Occipital and supraorbital transcutaneous nerve stimulation (OS-TNS) 3 106 100 2 3 0 100
 Transcranial direct current stimulation (tDCS) 1 32 100 0 0 0 0
 Transcranial alternating current stimulation 1 40 100 1 1 100 0
 Auricular transcutaneous vagus nerve stimulation 1 50 100 1 1 0 0
Magnetic stimulation
 Single-pulse transcranial magnetic stimulation (sTMS) 2 309 50 2 1 50 50
 Repetitive transcranial magnetic stimulation (rTMS) 1 201 0 1 1 100 100
Other
 Conditioned pain modulation
 (CPM)
3 476 100 3 3 0 33
 Intranasal kinetic oscillation stimulation 1 36 100 1 1 0 0

*All references for studies in this table are listed in the online supplementary references.

†Double-blind or better.

‡Percentage of efficacy studies in which either a primary or a secondary endpoint recommended by the International Headache Society was used. Safety studies were excluded from this calculation.

IHS, International Headache Society.